tbuckley/cabot-search huggingface dataset:
Prevalence of Hidradenitis Suppurativa
Authors: Abdulhadi Jfri, David Nassim, Elizabeth O’Brien, Wayne Gulliver, Georgios Nikolakis, Christos C. Zouboulis
Journal: JAMA Dermatology (2021)

Hidradenitis suppurativa/acne inversa (HS) is a chronic inflammatory skin disease characterized by occlusion of hair follicles as a primary pathogenic factor. There are scarce data regarding the prevalence of HS.To estimate overall HS prevalence.This review and meta-regression analysis was conducted using the Meta-analysis of Observational Studies in Epidemiology (MOOSE) reporting guideline. The academic search included PubMed, Cochrane registry, ClinicalTrials.gov, and evidence by NHS UK and Trip databases from inception through May 2020. To analyze HS prevalence, only cross-sectional studies or baseline assessments of longitudinal cohorts using census-based surveys or probabilistic and nonprobabilistic epidemiologic methods were considered. The search terms were (prevalence OR incidence OR epidemiology) AND (hidradenitis suppurativa OR acne inversa OR Verneuil's disease). No language restriction was applied.Original investigations that reported HS prevalence were included. After exclusion criteria were applied, 17 studies qualified for qualitative analysis, but only 16 studies were quantitatively assessed.Two reviewers extracted data by age, diagnostic criteria, presence of any comorbidity, sample sizes, continent/location, sex, and other characteristics. Assessment of bias risk used the Joanna Briggs Institute Critical Appraisal Instrument for Studies Reporting Prevalence Data using random-effects models to synthesize available evidence.Hidradenitis suppurativa prevalence (with 95% CI) among the overall population and among subgroups. Between-study heterogeneity was assessed (Cochran Q statistic) and quantified (I2 statistic).In 16 quantitatively assessed studies included, prevalence estimates were reported only from Western European and Scandinavian countries, the US, and Australia. Meta-analysis with random effects, after adjusting for publication bias in the prevalence estimates, revealed a 0.40% prevalence (95% CI, 0.26%-0.63%) for HS. Studies based on clinical samples revealed a higher pooled prevalence of HS (1.7%) than population-based studies (0.3%).The findings of this systematic review and meta-regression analysis may help facilitate policy formulation, channeling funding and guiding principles for better disease diagnosis using universal valid tools and management.
Demonstrating trustworthiness when collecting and sharing genomic data: public views across 22 countries
Authors: Richard Milne, Katherine I. Morley, Mohamed A. Almarri, Shamim Anwer, Jerome Atutornu, Elena E. Baranova, Paul Bevan, Maria Cerezo, Yali Cong, Alessia Costa, Christine Critchley, Josepine Fernow, Peter Goodhand, Qurratulain Hasan, Aiko Hibino, Gry Houeland, Heidi C. Howard, S. Zakir Hussain, Charlotta Ingvoldstad Malmgren, Vera L. Izhevskaya, Aleksandra Jędrzejak, Cao Jinhong, Megumi Kimura, Erika Kleiderman, Brandi Leach, Keying Liu, Deborah Mascalzoni, Álvaro Mendes, Jusaku Minari, Dianne Nicol, Emilia Niemiec, Christine Patch, Jack Pollard, Barbara Prainsack, Marie Rivière, Lauren Robarts, Jonathan Roberts, Virginia Romano, Haytham A. Sheerah, James Smith, Alexandra Soulier, Claire Steed, Vigdis Stefànsdóttir, Cornelia Tandre, Adrian Thorogood, Torsten H. Voigt, Nan Wang, Anne V. West, Go Yoshizawa, Anna Middleton
Journal: Genome Medicine (2021)

Abstract Background Public trust is central to the collection of genomic and health data and the sustainability of genomic research. To merit trust, those involved in collecting and sharing data need to demonstrate they are trustworthy. However, it is unclear what measures are most likely to demonstrate this. Methods We analyse the ‘Your DNA, Your Say’ online survey of public perspectives on genomic data sharing including responses from 36,268 individuals across 22 low-, middle- and high-income countries, gathered in 15 languages. We examine how participants perceived the relative value of measures to demonstrate the trustworthiness of those using donated DNA and/or medical information. We examine between-country variation and present a consolidated ranking of measures. Results Providing transparent information about who will benefit from data access was the most important measure to increase trust, endorsed by more than 50% of participants across 20 of 22 countries. It was followed by the option to withdraw data and transparency about who is using data and why. Variation was found for the importance of measures, notably information about sanctions for misuse of data—endorsed by 5% in India but almost 60% in Japan. A clustering analysis suggests alignment between some countries in the assessment of specific measures, such as the UK and Canada, Spain and Mexico and Portugal and Brazil. China and Russia are less closely aligned with other countries in terms of the value of the measures presented. Conclusions Our findings highlight the importance of transparency about data use and about the goals and potential benefits associated with data sharing, including to whom such benefits accrue. They show that members of the public value knowing what benefits accrue from the use of data. The study highlights the importance of locally sensitive measures to increase trust as genomic data sharing continues globally.
Association of the Comprehensive Care for Joint Replacement Model With Disparities in the Use of Total Hip and Total Knee Replacement
Authors: Caroline P. Thirukumaran, Yeunkyung Kim, Xueya Cai, Benjamin F. Ricciardi, Yue Li, Kevin A. Fiscella, Addisu Mesfin, Laurent G. Glance
Journal: JAMA Network Open (2021)

The Comprehensive Care for Joint Replacement (CJR) model is Medicare's mandatory bundled payment reform to improve quality and spending for beneficiaries who need total hip replacement (THR) or total knee replacement (TKR), yet it does not account for sociodemographic risk factors such as race/ethnicity and income. Results of this study could be the basis for a Medicare payment reform that addresses inequities in joint replacement care.
AB0508 PHYSICAL ACTIVITY IN TUNISIAN ADULTS WITH ANKYLOSING SPONDYLITIS
Authors: A. Feki, I. Sellami, R. Akrout, S. Ben Jemaa, Z. Gassara, M. Ezzeddine, M. H. Kallel, H. Fourati, S. Baklouti
Journal: Annals of the Rheumatic Diseases (2021)

Background: Physical activity (PA) is associated with multiple health-related benefits among the general population and adults with chronic diseases like Ankylosing spondylitis (AS) [1]. As known, AS affects primarily enthesis and can lead to loss of function and decreased mobility. Objectives: The aim of this study was to explore the PA levels of adults with AS and to examine associations between PA, sociodemographic characteristics, immunological features, disease activity and treatment type. Methods: Cross-sectional clinical and laboratory data were collected on 68 AS patients. BASDAI (Bath ankylosing spondylarthritis disease activity index) and BASFI (Bath ankylosing spondylarthritis functional index) were calculated. Physical activity was measured using IPAQ-SF (International Physical Activity Questionnaire-Short Form). Its items record the time spent on physical activity of three intensity levels (vigorous, moderate and walking) as well as the time spent on sitting (referred to as sedentary in this study) in the past week. Both continuous (expressed as metabolic equivalent of task (MET)-min /week) and categorical (3 levels proposed: low, moderate and high level of PA) scores of IPAQ-SF were determined. Sedentary time (median) was reported in minutes/week. A p value &lt; 0.05 was considered significant. Results: Cross-sectional clinical and laboratory data were collected on 68 AS patients. BASDAI (Bath ankylosing spondylarthritis disease activity index) and BASFI (Bath ankylosing spondylarthritis functional index) were calculated. Physical activity was measured using IPAQ-SF (International Physical Activity Questionnaire-Short Form). Its items record the time spent on physical activity of three intensity levels (vigorous, moderate and walking) as well as the time spent on sitting (referred to as sedentary in this study) in the past week. Both continuous (expressed as metabolic equivalent of task (MET)-min /week) and categorical (3 levels proposed: low, moderate and high level of PA) scores of IPAQ-SF were determined. Sedentary time (median) was reported in minutes/week. A p value &lt; 0.05 was considered significant. Conclusion: Our study proved that physical activity in people with AS decreased with age and activity disease with a concomitant increase in sedentary activity. Given the risks of developing secondary chronic disease as a result of low levels of physical activity, physical exercise should be recommended as part of comprehensive AS care. References: [1]Conigliaro P, Triggianese P, Ippolito F, Lucchetti R, Chimenti MS, Perricone R. Insights on the Role of Physical Activity in Patients with Rheumatoid Arthritis. Drug Dev Res. 2014;75:S54–6. Disclosure of Interests: None declared.
POS0816 PROGNOSTIC FACTORS FOR AGGRAVATED VASCULAR DAMAGE IN TAKAYASU ARTERITIS
Authors: R. Chen, L. Ma, Y. Liu, L. Ma, L. Jiang
Journal: Annals of the Rheumatic Diseases (2021)

Background: Takayasu arteritis is a rare disease characterized by inflammation in the aorta and its branches. Some patients were discovered to suffer the aggravated vascular damage (AVD), monitored by imaging techniques, even with the effective anti-inflammation treatment. But the general characteristics and the related prognostic factors of AVD in TA were unclear yet. Objectives: We aimed to describe the characteristics of the AVD and identify its prognostic factors in TA. Methods: From the living East China Takayasu arteritis cohort, patients who underwent at least two magnetic resonance angiography (MRA) examinations at Zhongshan Hospital from April 2009 to April 2019 were enrolled as the derivation cohort to explore the prognostic factors of AVD in MRA. An independent group of patients from May 2019 to July 2020 comprising the validation cohort were used to validate the nomogram formed by these prognostic factors. Results: Among 235 enrolled patients, 69 patients (29.3%) suffered AVD with the median follow-up of 14 months. The limb arteries were the most vulnerable and the aggravated vascular stenosis were the most commonly seen in AVD. Patients with AVD were younger, had higher complement 4 levels at baseline, and lower disease remission rate at 6 months. Multivariate cox regression analysis revealed that younger age (HR: 0.25-0.42, 95%CI: 0.09-0.91), higher CRP levels (HR = 2.57, 95%CI: 1.51–4.36) at baseline, and lower remission rate at 6 months (HR = 0.36, 95%CI: 0.21–0.64) were significant predictors. In the validation cohort of 65 patients, 19 cases had AVD. The predictive nomogram based on these factors achieved C-indices of 0.745 and 0.641 in the derivation and validation cohort respectively. Conclusion: Totally, 29.3% of patients suffered AVD, among which the aggravated vascular stenosis and limb arteries involvement were most commonly seen. Younger age, higher CRP at baseline, and lower disease remission rate at 6 months were prognostic factors for AVD. References: [1]M. Bredemeier, C.M. Rocha, M.V. Barbosa, E.H. Pitrez. One-year clinical and radiological evolution of a patient with refractory Takayasu’s arteritis under treatment with tocilizumab. Clin Exp Rheumatol 2012; 30 (Suppl. 70): S98-S100. Disclosure of Interests: None declared
Abstract 13589: Machine Learning-Incorporated Intravascular Optical Coherence Tomography-Fluorescence Lifetime Imaging (OCT-FLIm) Provides Automated and Comprehensive Structural-Biochemical Characterization of Coronary Atherosclerotic Plaques
Authors: Sunwon Kim, Hyeong Soo Nam, Woojae Kang, Joon Woo Song, Jeongmoo Han, Min Woo Lee, Hyun-Sang Park, Wang-Yuhl Oh, Hongki Yoo, Jin Won Kim
Journal: Circulation (2019)

Introduction: Fluorescence lifetime imaging (FLIm) is a novel approach allowing biochemical characterization of atherosclerotic plaque without contrast agent. However, advanced multispectral FLIm s...
Association of Low-Value Care Exposure With Health Care Experience Ratings Among Patient Panels
Authors: Prachi Sanghavi, J. Michael McWilliams, Aaron L. Schwartz, Alan M. Zaslavsky
Journal: JAMA Internal Medicine (2021)

Patient reviews of health care experiences are increasingly used for public reporting and alternative payment models. Critics have argued that this incentivizes physicians to provide more care, including low-value care, undermining efforts to reduce wasteful practices.To assess associations between rates of low-value service provision to a primary care professional (PCP) patient panel and patients' ratings of their health care experiences.This quality improvement study used Medicare fee-for-service claims from January 1, 2007, to December 31, 2014, for a random 20% sample of beneficiaries to identify beneficiaries for whom each of 8 low-value services could be ordered but would be considered unnecessary. The study also used health care experience reports from independently sampled beneficiaries who responded to the 2010-2015 Consumer Assessment of Healthcare Providers and Systems (CAHPS) Medicare fee-for-service survey. Statistical analysis was performed from January 1, 2019, to December 9, 2020.The main outcomes were health care experience ratings from Medicare beneficiaries who responded to the CAHPS survey from 2 domains, namely "Your Health Care in the Last 6 Months" (overall health care, office wait time, timely access to nonurgent care, and timely access to urgent care) and "Your Personal Doctor" (overall personal physician and a composite score for interactions with personal physician). Beneficiaries in both samples were attributed to the PCP with whom they had the most spending. For each PCP, a composite score of low-value service exposure was constructed using the 20% sample; this score represented the adjusted relative propensity of the PCP patient panel to receive low-value care. The association between low-value service exposure and health care experience ratings reported by the CAHPS respondents in the PCP patient panel was estimated using regression analysis.The final sample had 100 743 PCPs, with a mean of approximately 258 patients per PCP. Only 1 notable association was found; more low-value care exposure was associated with more frequent reports of having to wait more than 15 minutes after the scheduled time of an appointment (a mean of 0.448 points lower CAHPS score on a 10-point scale for PCP patient panels who received the most low-value care vs the least low-value care). Although some other associations were statistically significant, their magnitudes were substantially smaller than those typically considered meaningful in other CAHPS literature and were inconsistent in direction across levels of low-value service exposure.This quality improvement study found that more low-value care exposure for a PCP patient panel was not associated with more favorable patient ratings of their health care experiences.
NDNF interneurons in layer 1 gain-modulate whole cortical columns according to an animal’s behavioral state
Authors: Katayun Cohen-Kashi Malina, Emmanouil Tsivourakis, Dahlia Kushinsky, Daniella Apelblat, Stav Shtiglitz, Eran Zohar, Michael Sokoletsky, Gen-ichi Tasaka, Adi Mizrahi, Ilan Lampl, Ivo Spiegel
Journal: Neuron (2021)
POS1312 DRUG SURVIVAL FOR IL-6 INHIBITOR TOCILIZUMAB: DATA FROM A SINGLE-CENTER OBSERVATION
Authors: E. Krekhova, E. Alexeeva, T. Dvoryakovskaya, K. Isaeva, R. Denisova, O. Lomakina, A. Mamutova, A. Chomakhidze, A. Fetisova, M. Gautier, I. Kriulin, I. Tsulukiya
Journal: Annals of the Rheumatic Diseases (2021)

Background: The efficacy of tocilizumab for treatment patients with systemic juvenile idiopathic arthritis (sJIA) was demonstrated before. We want to describe tocilizumab drug survival based on data from a single-center observation. Objectives: To analyze the drug survival of tocilizumab in patients with sJIA treated at the National Medical Research Center of Children`s health, Moscow, Russia. Methods: Medical records from sJIA patients treated with tocilizumab (TOC) were analyzed retrospectively from the National Medical Research Center of Children`s health, Moscow, Russia. Results: One hundred ninety-two patients presenting with sJIA were included in this observation, with a median age at treatment initiation of 7,2 (interquartile range, IQR 3,9-10,8) years and a median disease duration of 1,9 (IQR 0,4-5,9) years. All patients had been bio-naive. TOC therapy was highly effective in patients with sJIA. At 6 month of follow-up 148/172 (86%) patients achieved inactive disease according the criteria C. Wallace, disease activity persisted in 24/172 (14%) patients. At 1 year of medication 139/150 (92%) patients had inactive disease. We analyzed the reason of TOC withdrawal retrospectively. A total of 82/192 drug withdrawals were performed. TOC was discontinued due to primary ineffectiveness in 4 patients, due to secondary ineffectiveness in 39 patients. 33 patients achieved drug-free remission. Six patients developed side effects that required discontinuation of TOC therapy (4 patients had allergic reactions, 1 patient developed tuberculosis, 1 patient had severe neutropenia). 47/82 patients were switched on other biologic drug: on canakinumab (31), on TNF-inhibitors (11), on rituximab (5). In summary, TOC was canceled in 49/192 (25%) patients due to ineffectiveness or AEs in our cohort. Conclusion: These results demonstrated that TOC is highly effective as the first biologic drug in patients with sJIA. Our observations have shown a good tolerability and survival of the IL-6 inhibitor TOC in patients with sJIA treated in a real-world clinical setting. Disclosure of Interests: None declared
POS0794 INCIDENCE AND PHENOTYPE OF ANTIPHOSPHOLIPID SYNDROME (APS) AFTER PREECLAMPSIA
Authors: S. Amylidi-Mohr, M. Karakitsiou, R. Braun, F. Förger, E. Rexhaj, L. Raio
Journal: Annals of the Rheumatic Diseases (2021)

Background: Obstetric Antiphospholipid syndrom (oAPS) is induced by antiphospholipid antibodies (aPL) and associated with specific pregnancy complications. oAPS requires the combination of at least one obstetrical and one laboratory criteria (in 2 or more occasions at least 12 weeks apart). Multiple aPL positivity, lupus anticoagulant (LA) or persistently high aPL titers is defined as high risk aPL profile. “Non-criteria” oAPS are cases not fulfilling the clinical criteria. Objectives: To investigate the incidence of aPL after preeclampsia and the association of phenotypes of oAPS and pregnancy outcome. Methods: The present retrospective cohort analysis included women followed up after preeclampsia. Anti-PL (LA, aCL, anti-β2GBI of IgG and IgM isotype) are assessed 8 to 12 weeks after PE and if positive, again at least 12 weeks apart. According to the ISSHP PE is classified as severe if the blood pressure exceeds 160/110mmHg, or is associated with HELLP syndrome, or eclampsia. FGR is defined as estimated fetal weight &lt;5 th , and birth weight &lt;10 th percentile, and/or pathologic fetal Doppler. Results: Complete clinical and laboratory data were available for 99 women over a period of 6 years. 38.4% delivered &lt;34 + 0 weeks. PE was severe in 63.6% of cases, and the incidence of FGR was 58.9%. HELLP syndrome was diagnosed in 34.3% and in 4 cases it was isolated. The prevalence of aPL was 35 (35.4%) at first evaluation, and 23 (23.2%) were still positive 12 weeks apart. 14/99 (14.1%) cases fulfilled the definition of classical oAPS, and 9/99 (9.1%) delivered &gt;34 weeks (“non-criteria oAPS”). Of interest, the incidende og high risk aPL profiles was similar in both groups (64.3% vs. 77.8%; p=NS). The incidence of HELLP syndrome was higher in the presence of APS (APS: 9/23 [39.1%] vs. 21/76 [27.6%]; p=NS). 3 out of 4 cases with isolated HELLP syndrome were associated with high risk aPL profiles. Overall, aCL IgG was the dominant aPL. 32/35 (91.4%) and 22/23 (95.7%) had positive aCL at first and second investigation, respectively (p=NS). An aCL IgG titer &gt;32.8CU at first assessment yield a LR of 10 for persistent aCL with a sensitivity and specificity of 91.3% and 90.9%, respectively. Conclusion: Classical and “non-criteria” obstetrical APS show a similar aPL pattern and distribution of aPL phenotypes regardless of gestational age at delivery. aCL IgG is the dominant aPL antibody and is highly predictive for aPL persistence at follow up. HELLP syndrome may be an additional feature of oAPS, in particular the isolated form. However, more studies are necessary to explore this possible association. References: [1]Tektonidou MG et al, EULAR recommendations for the management of antiphospholipid syndrome in adults Ann Rheum Dis. 2019 Oct;78(10):1296-1304. doi: 10.1136/annrheumdis-2019-215213. Epub 2019 May 15. Disclosure of Interests: None declared
AB0732 JUVENILE IDIOPATHIC ARTHRITIS IN ADULTHOOD
Authors: N. Ben Chekaya, S. Bouden, A. Ben Tekaya, O. Ben Saidane, R. Tekaya, I. Mahmoud, L. Abdelmoula
Journal: Annals of the Rheumatic Diseases (2021)

Background: Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease of unknown aetiology in childhood. Approximately 40- 60% of patients with juvenile idiopathic arthritis (JIA) have continuous or recurrent disease activity extending into adulthood. Objectives: The aim of this study was to evaluate the clinical, biological and radiological course of JIA in adulthood. Methods: A retrospective study including 35 patients was conducted between 2010 and 2019. The patients enrolled met the ILAR criteria for the diagnosis of JIA. Patients with JIA older than 20 years were included. Data regarding sociodemographic features, Physical growth, disease activity, biological and radiological parameters were analysed. Results: Thirty one patients were recruited. The sex ratio was 0.53. The mean age at the time of the study was 38.9 years [20-69]. The mean age of the disease onset was 9 years [3-16]. These patients were assigned to discrete JIA categories: rheumatoid factor positive polyarthritis (47.7%), rheumatoid factor negative polyarthritis (23.9%), oligoarthritis (14.2%), enthesitis-related arthritis (9.5%), and psoriatic arthritis (4.7%).A failure to thrive was seen in 33.3% of patients. Overweight and obesity were found in 38% and 19% of patients, respectively. Biological inflammatory syndrome was noted in 52% of patients, and 65.2% had active disease. Hip involvement was noted in 43.5% of patients and 17.4% of them had a total hip replacement. Sixteen patients had neck pain and the imagining showed an atloid-axoid dislocation in 50% of them. Radiographs showed a joint destruction in 60.9% of patients and a wrist arthritis was the most frequent involvement. Conclusion: Most of our included patients maintain active disease and have functional impairment in adulthood. Disclosure of Interests: None declared
Liquid biopsy for therapy monitoring in early-stage non-small cell lung cancer
Authors: Misako Nagasaka, Mohammed Hafiz Uddin, Mohammed Najeeb Al-Hallak, Sarah Rahman, Suresh Balasubramanian, Ammar Sukari, Asfar S. Azmi
Journal: Molecular Cancer (2021)

Abstract Liquid biopsy is now considered a valuable diagnostic tool for advanced metastatic non-small cell lung cancer (NSCLC). In NSCLC, circulating tumor DNA (ctDNA) analysis has been shown to increase the chances of identifying the presence of targetable mutations and has been adopted by many clinicians owing to its low risk. Serial monitoring of ctDNA may also help assess the treatment response or for monitoring relapse. As the presence of detectable plasma ctDNA post-surgery likely indicates residual tumor burden, studies have been performed to quantify plasma ctDNA to assess minimal residual disease (MRD) in early-stage resected NSCLC. Most data on utilizing liquid biopsy for monitoring MRD in early-stage NSCLC are from small-scale studies using ctDNA. Here, we review the recent research on liquid biopsy in NSCLC, not limited to ctDNA, and focus on novel methods such as micro RNAs (miRNA) and long non-coding (lncRNA).